DoD's $17.8M Contract with Maritime Materials Technologies (M2T) for R&D in Biotechnology

Contract Overview

Contract Amount: $17,833,778 ($17.8M)

Contractor: Leidos, Inc.

Awarding Agency: Department of Defense

Start Date: 2019-11-04

End Date: 2024-09-30

Contract Duration: 1,792 days

Daily Burn Rate: $10.0K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 3

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: MARITIME MATERIALS TECHNOLOGIES (M2T)

Place of Performance

Location: RESTON, FAIRFAX County, VIRGINIA, 20190

State: Virginia Government Spending

Plain-Language Summary

Department of Defense obligated $17.8 million to LEIDOS, INC. for work described as: MARITIME MATERIALS TECHNOLOGIES (M2T) Key points: 1. Contract awarded to Maritime Materials Technologies (M2T) for $17.8M. 2. Competition was full and open, indicating a competitive bidding process. 3. The contract is for Research and Development in Biotechnology. 4. Leidos, Inc. is listed as a competitor, suggesting a competitive market.

Value Assessment

Rating: fair

The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. The award amount of $17.8M is moderate for R&D, but the final cost will depend on project execution.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting that multiple vendors had the opportunity to bid. This method generally promotes price discovery and competitive pricing.

Taxpayer Impact: The taxpayer impact is moderate, with the potential for value depending on the success of the R&D outcomes.

Public Impact

Advancement in biotechnology research could lead to new defense capabilities. Investment in R&D is crucial for maintaining technological superiority. The contract duration of nearly 5 years allows for substantial research progress.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Cost Plus Fixed Fee contract type can incentivize higher costs.
  • Potential for scope creep in R&D projects.
  • Limited information on specific deliverables and success metrics.

Positive Signals

  • Full and open competition ensures a competitive bidding process.
  • Focus on critical R&D in biotechnology.
  • Long-term contract allows for sustained research efforts.

Sector Analysis

This contract falls within the Research and Development sector, specifically focusing on biotechnology. Spending in this area is critical for innovation and national security, with benchmarks varying widely based on project scope and complexity.

Small Business Impact

The data does not indicate if small businesses were involved in this contract, either as prime contractors or subcontractors. Further analysis would be needed to determine small business participation.

Oversight & Accountability

Oversight by the Department of Defense, specifically DARPA, is expected to be rigorous given the agency's focus on cutting-edge research. However, the effectiveness of oversight depends on detailed performance metrics and regular reviews.

Related Government Programs

  • Research and Development in Biotechnology (except Nanobiotechnology)
  • Department of Defense Contracting
  • Defense Advanced Research Projects Agency Programs

Risk Flags

  • Cost Plus Fixed Fee contract structure.
  • Potential for R&D project scope creep.
  • Lack of specific performance metrics in provided data.
  • Limited insight into small business participation.

Tags

research-and-development-in-biotechnolog, department-of-defense, va, definitive-contract, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $17.8 million to LEIDOS, INC.. MARITIME MATERIALS TECHNOLOGIES (M2T)

Who is the contractor on this award?

The obligated recipient is LEIDOS, INC..

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Advanced Research Projects Agency).

What is the total obligated amount?

The obligated amount is $17.8 million.

What is the period of performance?

Start: 2019-11-04. End: 2024-09-30.

What are the specific research objectives and expected outcomes of this biotechnology R&D contract?

The specific research objectives and expected outcomes are not detailed in the provided data. Typically, DARPA contracts aim for transformative technological advancements with potential dual-use applications. Further documentation would be required to ascertain the precise goals, such as developing novel materials, enhancing biological sensing capabilities, or improving biotechnological processes for defense applications.

What are the key performance indicators (KPIs) used to measure the success of this Cost Plus Fixed Fee contract?

Key performance indicators for a Cost Plus Fixed Fee contract in R&D are usually tied to milestones, technical progress, and adherence to research plans. Success would be measured by the achievement of defined research goals, successful demonstration of prototypes or concepts, and timely reporting of findings. The fixed fee component incentivizes the contractor to complete the work efficiently within the agreed-upon scope.

How does the $17.8M investment compare to similar biotechnology R&D contracts within the DoD or other federal agencies?

The $17.8M award is a moderate investment for a multi-year R&D contract in biotechnology. Benchmarking against similar contracts requires access to a broader dataset of federal procurements. However, for specialized R&D projects managed by agencies like DARPA, this amount is within a typical range, reflecting the complexity and long-term nature of cutting-edge scientific research.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTDEFENSE (OTHER) R&D

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: BASIC RESEARCH

Solicitation ID: HR001119S0011

Offers Received: 3

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Leidos Holdings, Inc.

Address: 11951 FREEDOM DR, RESTON, VA, 20190

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $18,018,800

Exercised Options: $18,018,800

Current Obligation: $17,833,778

Actual Outlays: $1,015,227

Subaward Activity

Number of Subawards: 41

Total Subaward Amount: $3,739,547

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline

Start Date: 2019-11-04

Current End Date: 2024-09-30

Potential End Date: 2024-09-30 00:00:00

Last Modified: 2025-08-28

More Contracts from Leidos, Inc.

View all Leidos, Inc. federal contracts →

Other Department of Defense Contracts

View all Department of Defense contracts →

Explore Related Government Spending